Skip to main content
. Author manuscript; available in PMC: 2010 Jan 28.
Published in final edited form as: Sci Signal. 2009 Nov 17;2(97):ra73. doi: 10.1126/scisignal.2000431

Fig. 4.

Fig. 4

PKM2 is specifically phosphorylated at Y105 in various cancer cell lines. (A) Immunoblotting detects Y105 phosphorylation of PKM2 in diverse lung cancer (A549, H1299), breast cancer (MDA-MB231), prostate cancer (PC3, Du145), and leukemia (HEL, KG-1a, Mo91, Molm14, K562) cell lines, but not in two prostate cancer cell lines, LNCaP and 22Rv. Immunoblotting shows that targeting BCR-ABL by imatinib in K562 cells (B), JAK2 by AG490 in HEL cells (C), and FLT3 by TKI258 in Molm14 cells (D) decreases phosphorylation of PKM2 Y105.